•  
  •  
  •  
  •  

2026-07-24 11:43:54

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan

Keywords Selected:  Biosimilar

Stock Report

  • OneSource Specialty Pharma and Formycon AG announce Strategic Manufacturing Partnership for Biosimilars
  • Dr. Reddy's Laboratories Announces Launch of Oral Semaglutide Biosimilar 'Obeda®' (tablets) in India
  • CuraTeQ Biologics Secures Health Canada NOC for Bevqolva™ Bevacizumab Biosimilar
  • Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™, Biosimilars to Prolia® and Xgeva®
  • CuraTeQ Biologics announces Positive Top-Line Results for Phase 3 Study of Omalizumab Biosimilar BP11
  • CuraTeQ Biologics Pvt Ltd enters into agreement with STADA Arzneimittel AG
  • Zydus Lifesciences announces successful clinical development of Pembrolizumab biosimilar FYB206, marking a milestone toward USFDA filing
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Zydus launches biosimilar Aflibercept 2 mg ANYRA™ for advancing ophthalmic care
  • CuraTeQ Biologics Pvt Ltd and BioFactura Inc, USA to terminate agreement mutually
  • Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab
  • Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
  • Zydus launches biosimilar Denosumab 120 mg SC - protecting bone health in cancer patients
  • Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
  • Lupin Receives Approval from U.S. FDA for Biosimilar Armlupeg - Pegfilgrastim-unne
  • Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V., a Biosimilar to Stelara®
  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Biocon Biologics Collaborates with National Cancer Society Malaysia

Latest Post

  • Mphasis Reports 17.5% YoY Revenue Growth in Q1 FY27; Secures $461 Million in New Deal Wins Driven by AI Demand
  • Fractal Analytics Reports 20% Revenue Growth and 92% Surge in Net Income for Q1 FY27
  • Route Mobile Ltd Financial Results Reveal Strong Operational Top-Line Expansion for Q1 FY27 as Revenue Reaches ₹1,151.51 Crore
  • CyberTech Systems and Software Limited Reports Q1 FY27 Net Profit Up 16% YoY to ₹9.48 Crore as Operational Revenue Reaches ₹68.45 Crore
  • ACME Solar operationalizes 3.62 GWh Battery Energy Storage System projects in Rajasthan


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025